Influenza News and Research

Latest Influenza News and Research

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

Paper-strip test could identify counterfeit versions of faked medicines in the world

In a thrust against the major problem of counterfeit medicines sold in developing countries, which causes thousands of illnesses and deaths annually, scientists today described development of a simple, paper-strip test that people could use to identify counterfeit versions of one of the most-frequently faked medicines in the world.

20 Aug 2012

Pennsylvania Department of Health reports four confirmed and six probable cases of H3N2v flu

The Pennsylvania Department of Health today reported four confirmed and six probable human cases of influenza due to a new strain of the flu known as H3N2v.

18 Aug 2012

FibeBiotics aims to prove benefits of polysaccharides in clinical trials

Staying healthy requires constantly stimulating the immune system. Ingesting non-digestible fibres such as polysaccharides is thought to help. Yet companies including such ingredients in their food products cannot claim that they boost the immune system. At least, not until they have been scientifically tested and proven in clinical trials. Only then, would the European Food Safety Agency (EFSA) allow such health claims.

18 Aug 2012

Retail medical clinic visits increase four-fold from 2007-2009

Fast-growing retail medical clinics are attracting more older patients and delivering more preventive care, particularly flu shots and other vaccinations, according to a new study from the RAND Corporation.

17 Aug 2012

Study helps explain how large DNA viruses undergo rapid evolution

Scientists have discovered that poxviruses, which are responsible for smallpox and other diseases, can adapt to defeat different host antiviral defenses by quickly and temporarily producing multiple copies of a gene that helps the viruses to counter host immunity.

17 Aug 2012

Researchers identify molecular and protein signatures that predict HCV virus-induced liver injury

Researchers have discovered molecular and protein signatures that predict rapid onset of liver damage in hepatitis C patients following a liver transplant. The markers appeared soon after transplant and well before clinical evidence of liver damage.

17 Aug 2012

Be ‘medicinewise’ with cough and cold medicines in young children

NPS MedicineWise is urging parents and health professionals to heed the advice from the Therapeutic Goods Administration (TGA) this week restricting the use of cough and cold medicines to treat young children amidst concerns they have limited efficacy and may even be harmful.

16 Aug 2012

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine.

16 Aug 2012

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

16 Aug 2012

Six manufacturers receive FDA approval to produce 2012-2013 flu vaccines

The U.S. Food and Drug Administration announced today that it has approved the 2012-2013 influenza (flu) vaccine formulation for all six manufacturers licensed to produce and distribute the vaccines in the United States.

14 Aug 2012

Orally effective FluCide anti-influenza drug candidate

NanoViricides, Inc. announced today that an anti-influenza drug candidate under its FluCide program is effective when given orally. The Company has received information that a FluCide drug candidate designed for oral administration has shown very strong efficacy in corresponding animal studies.

13 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

Drug molecules designed for influenza may be adapted to treat other viruses

St. Jude Children's Research Hospital study shows how compounds blocking an enzyme universal to all influenza viruses may allow development of new antiviral drugs that also avoid the problem of drug resistance

3 Aug 2012

GSK begins shipping the first lots of 2012-2013 seasonal influenza vaccines

GlaxoSmithKline announced today it has begun shipping the first lots of 2012-2013 FluLaval (Influenza virus vaccine) and Fluarix (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers.

1 Aug 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

University of Texas Medical Branch at Galveston researchers have been awarded a two-year, $1.25 million National Institutes of Health grant to develop a method of custom-growing human lung tissue to make a three-dimensional model for biomedical studies.

30 Jul 2012

Influenza News and Research

Latest Influenza News and Research

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Paper-strip test could identify counterfeit versions of faked medicines in the world

Pennsylvania Department of Health reports four confirmed and six probable cases of H3N2v flu

FibeBiotics aims to prove benefits of polysaccharides in clinical trials

Retail medical clinic visits increase four-fold from 2007-2009

Study helps explain how large DNA viruses undergo rapid evolution

Researchers identify molecular and protein signatures that predict HCV virus-induced liver injury

Be ‘medicinewise’ with cough and cold medicines in young children

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

Six manufacturers receive FDA approval to produce 2012-2013 flu vaccines

Orally effective FluCide anti-influenza drug candidate

BioDiem granted European patent for antimicrobial drug

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Drug molecules designed for influenza may be adapted to treat other viruses

GSK begins shipping the first lots of 2012-2013 seasonal influenza vaccines

Australia's top medical researchers for 2012 announced

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Promising implications for improving cellular immunotherapy for treatment of cancer

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Influenza News and Research

Latest Influenza News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in